Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Radiologic responses in cynomolgous macaques for assessing tuberculosis chemotherapy regimens.

Lin PL, Coleman T, Carney JP, Lopresti BJ, Tomko J, Fillmore D, Dartois V, Scanga C, Frye LJ, Janssen C, Klein E, Barry CE 3rd, Flynn JL.

Antimicrob Agents Chemother. 2013 Jun 24. [Epub ahead of print]

2.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
3.

Early Changes by (18)Fluorodeoxyglucose positron emission tomography coregistered with computed tomography predict outcome after Mycobacterium tuberculosis infection in cynomolgus macaques.

Coleman MT, Maiello P, Tomko J, Frye LJ, Fillmore D, Janssen C, Klein E, Lin PL.

Infect Immun. 2014 Jun;82(6):2400-4. doi: 10.1128/IAI.01599-13. Epub 2014 Mar 24.

4.

Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment.

Davis SL, Nuermberger EL, Um PK, Vidal C, Jedynak B, Pomper MG, Bishai WR, Jain SK.

Antimicrob Agents Chemother. 2009 Nov;53(11):4879-84. doi: 10.1128/AAC.00789-09. Epub 2009 Sep 8.

5.

Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing.

Lin PL, Ford CB, Coleman MT, Myers AJ, Gawande R, Ioerger T, Sacchettini J, Fortune SM, Flynn JL.

Nat Med. 2014 Jan;20(1):75-9. doi: 10.1038/nm.3412. Epub 2013 Dec 15.

6.

90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT.

Bienert M, McCook B, Carr BI, Geller DA, Sheetz M, Tutor C, Amesur N, Avril N.

Eur J Nucl Med Mol Imaging. 2005 Jul;32(7):778-87. Epub 2005 Mar 17.

PMID:
15772860
7.

FDG-PET imaging in HIV infection and tuberculosis.

Sathekge M, Maes A, Van de Wiele C.

Semin Nucl Med. 2013 Sep;43(5):349-66. doi: 10.1053/j.semnuclmed.2013.04.008. Review.

PMID:
23905617
8.

(18)F-FDG positron-emission tomography/computed tomography findings of radiographic lesions suggesting old healed tuberculosis.

Jeong YJ, Paeng JC, Nam HY, Lee JS, Lee SM, Yoo CG, Kim YW, Han SK, Yim JJ.

J Korean Med Sci. 2014 Mar;29(3):386-91. doi: 10.3346/jkms.2014.29.3.386. Epub 2014 Feb 27.

9.

Monitoring therapy with MEK inhibitor U0126 in a novel Wilms tumor model in Wt1 knockout Igf2 transgenic mice using 18F-FDG PET with dual-contrast enhanced CT and MRI: early metabolic response without inhibition of tumor growth.

Flores LG 2nd, Yeh HH, Soghomonyan S, Young D, Bankson J, Hu Q, Alauddin M, Huff V, Gelovani JG.

Mol Imaging Biol. 2013 Apr;15(2):175-85. doi: 10.1007/s11307-012-0588-5.

11.

Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.

Mileshkin L, Hicks RJ, Hughes BG, Mitchell PL, Charu V, Gitlitz BJ, Macfarlane D, Solomon B, Amler LC, Yu W, Pirzkall A, Fine BM.

Clin Cancer Res. 2011 May 15;17(10):3304-15. doi: 10.1158/1078-0432.CCR-10-2763. Epub 2011 Mar 1.

12.

2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography demonstrates target inhibition with the potential to predict anti-tumour activity following treatment with the AKT inhibitor AZD5363.

Maynard J, Ricketts SA, Gendrin C, Dudley P, Davies BR.

Mol Imaging Biol. 2013 Aug;15(4):476-85. doi: 10.1007/s11307-013-0613-3.

PMID:
23344784
13.
14.

Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer.

Deniaud-Alexandre E, Touboul E, Lerouge D, Grahek D, Foulquier JN, Petegnief Y, Grès B, El Balaa H, Keraudy K, Kerrou K, Montravers F, Milleron B, Lebeau B, Talbot JN.

Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1432-41. Epub 2005 Aug 25.

PMID:
16125870
15.

Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer.

Ueda S, Tsuda H, Asakawa H, Omata J, Fukatsu K, Kondo N, Kondo T, Hama Y, Tamura K, Ishida J, Abe Y, Mochizuki H.

BMC Cancer. 2008 Jun 9;8:165. doi: 10.1186/1471-2407-8-165.

16.

Advances in imaging of tuberculosis: the role of ¹⁸F-FDG PET and PET/CT.

Vorster M, Sathekge MM, Bomanji J.

Curr Opin Pulm Med. 2014 May;20(3):287-93. doi: 10.1097/MCP.0000000000000043. Review.

PMID:
24614238
17.

A computational pipeline for quantification of pulmonary infections in small animal models using serial PET-CT imaging.

Bagci U, Foster B, Miller-Jaster K, Luna B, Dey B, Bishai WR, Jonsson CB, Jain S, Mollura DJ.

EJNMMI Res. 2013 Jul 23;3(1):55. doi: 10.1186/2191-219X-3-55.

18.

Nuclear medicine imaging in tuberculosis using commercially available radiopharmaceuticals.

Sathekge M, Maes A, D'Asseler Y, Vorster M, Van de Wiele C.

Nucl Med Commun. 2012 Jun;33(6):581-90. doi: 10.1097/MNM.0b013e3283528a7c. Review.

PMID:
22422098
19.

[Impact of computed tomography (CT) and 18F-deoxyglucose-coincidence detection emission tomography (FDG-CDET) image fusion for optimisation of conformal radiotherapy in non-small-cell lung cancers].

Deniaud-Alexandre E, Touboul E, Lerouge D, Grahek D, Foulquier JN, Petegnief Y, Grès B, El Balaa H, Keraudy K, Kerrou K, Montravers F, Milleron B, Lebeau B, Talbot JN.

Cancer Radiother. 2005 Sep;9(5):304-15. Epub 2005 Aug 8. French.

PMID:
16087377
20.

In vivo imaging of schistosomes to assess disease burden using positron emission tomography (PET).

Salem N, Balkman JD, Wang J, Wilson DL, Lee Z, King CL, Basilion JP.

PLoS Negl Trop Dis. 2010 Sep 21;4(9). pii: e827. doi: 10.1371/journal.pntd.0000827.

Items per page

Supplemental Content

Write to the Help Desk